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One proposed contributory mechanism for depressed ventricular perfor- 
mance after hypothermic, hyperkalemic cardioplegic arrest is a reduction 
in myocyte contractile function caused by alterations in intracellular 
calcium homeostasis. Because 2,3-butanedione monoxime decreases intra- 
cellular calcium transients, this study tested the hypothesis that 2,3- 
butanedione monoxime supplementation f the hyperkalemic cardioplegic 
solution could preserve isolated myocyte contractile function after hypo- 
thermic, hyperkalemic cardioplegic arrest. Myocytes were isolated from the 
left ventricles of six pigs. Magnitude and velocity of myocyte shortening 
were measured after 2 hours of incubation under normothermic conditions 
(37 ° C, standard medium), hypothermic, hyperkalemic cardioplegic arrest 
(4 ° C in Ringer's olution with 20 mEq potassium chloride), and hypother- 
mic, hyperkalemic ardioplegic arrest with 2,3-butanedione monoxime 
supplementation (4 ° C in Ringer's olution with 20 mEq potassium chloride 
and 20 mmol/L 2,3-butanedione monoxime). Because ~-adrenergic agonists 
are commonly employed after cardioplegic arrest, myocyte contractile 
function was examined in the presence of the ~-agonist isoproterenol (25 
nmol/L). Hypothermic, hyperkalemic cardioplegic arrest and rewarming 
reduced the velocity (32%) and percentage ofmyocyte shortening (27%, p < 
0.05). Supplementation with 2,3-butanedione monoxime normalized myo- 
cyte contractile function after hypothermic, hyperkalemic ardioplegic 
arrest. Although 13-adrenergic stimulation significantly increased myocyte 
contractile function under normothermic conditions and after hypother- 
mic, hyperkalemic cardioplegic arrest, contractile function of myocytes 
exposed to l~-agonist after hypothermic, hyperkalemic cardioplegic arrest 
remained significantly reduced relative to the normothermic control group. 
Supplementation with 2,3-butanedione monoxime restored i~-adrenergic 
responsiveness of myocytes after hypothermic, hyperkalemic cardioplegic 
arrest. Thus, supplementation f a hyperkalemic cardioplegic solution with 
2,3-butanedione monoxime had direct and beneficial effects on myocyte 
contractile function and 18-adrenergic responsiveness after cardioplegic 
arrest. A potential mechanism for the effects of 2,3-butanedione monoxime 
includes modulation of intracellular calcium transients or alterations in 
sensitivity to calcium. Supplementation with 2,3-butanedione monoxime 
may have clinical utility in improving myocardial contractile function after 
hypothermic, hyperkalemic cardioplegic arrest. (J THORAC CARDIOVASC 
SURG 1996;111:621-9) 
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M Yocardial preservation during cardiopulmonary bypass for cardiac surgery has traditionally in- 
volved the use of hypothermic, hyperkalemic cardio- 
plegia. 1 The fundamental basis for the clinical use of 
hyperkalemic ardioplegia is that it causes rapid 
membrane depolarization and produces a quiescent 
heart. 2 This membrane depolarization i  the pres- 
ence of elevated extracellular potassium concentra- 
tions results in a cessation of contractile activity, 
thereby reducing metabolic demands within the 
myocyte.3, 4 Extracellular hyperkalemia has signifi- 
cant effects on ionic homeostasis, however, and 
causes an intracellular calcium overload state that, 
with reperfusion, has been shown to result in alter- 
ations in contractile performance and abnormal 
regulation of intracellular enzyme systems and vol- 
ume regulatory mechanisms, s-l° Furthermore, any 
myocyte ischemia during cardioplegic arrest contrib- 
utes to the increased intracellular concentration of 
free calcium and myocyte damage. 11-14 Because 
increases in intracellular calcium associated with 
hyperkalemic ardioplegic arrest appear to play a 
pivotal role in myocyte contractile dysfunction and 
derangements in metabolic processes, prevention of 
an elevated intracellular calcium state during hy- 
perkalemic ardioplegic arrest may preserve myo- 
cyte contractile function. 
The agent 2,3-butanedione monoxime (BDM) has 
the ability to uncouple cardiac excitation from con- 
traction, prolong myocardial ischemic tolerance, 
and protect ischemic myocardium from calcium- 
induced adenosine triphosphate (ATP) loss and the 
damaging effects of ischemic contracture. 15' 16 Al- 
though the exact mechanism by which BDM affects 
contractile activity is not completely understood, in 
part BDM appears to cause a reduction in myofi- 
brillar sensitMty to calcium. 17-19 Moreover, BDM has 
been shown to decrease intracellular calcium tran- 
sients secondary to a reduction in the release of 
calcium from the sarcoplasmic reticulum and a reduc- 
tion in the transsarcolemmal calcium lCttlX. 1s'20-22 
BDM-induced decreases in myocyte calcium tran- 
sients and myofibrillar sensitivity to calcium may prove 
useful in attenuating the derangements in myocyte 
contractile function and metabolic regulatory pro- 
cesses associated with a calcium overload state after 
hyperkalemic cardioplegic arrest. Our purpose in this 
study was therefore to examine the effects of BDM 
supplementation of hyperkalemic ardioplegia on 
myocyte contractile function and cellular swelling in an 
isolated myocyte model of hypothermic, hyperkalemic 
cardioplegic arrest o better understand both optimal 
myocardial preservation and contractile dysfunction 
associated with hyperkalemic cardioplegic arrest. 
Methods 
Myocyte isolation and contraction. Myocyte isolation 
and measurement of myocyte contractile function were 
performed according to previously described methods, 
well characterized by reports from this laboratory. & 9. 23 
Yorkshire swine were the source of myocytes used in this 
study. All animals were cared for and treated in accor- 
dance with the "Guide for the Care and Use of Labora- 
tory Animals" prepared by the Institute of Laboratory 
Animal Resources and published by the National Insti- 
tutes of Health (NIH Publication No. 86-23, revised 1985). 
Surgical anesthesia was provided with 2% isoflurane in 
oxygen, and the heart was quickly removed and placed in 
an oxygenated Krebs solution. A portion of the left 
ventricular f ee wall (5 × 5 cm) containing the circumflex 
artery was excised and used for myocyte isolation. After 
cannulation of the circumflex artery and ligation of distal 
branches, the tissue was rinsed free of blood with 30 ml 
modified Krebs solution containing 5 mmol/L nitrilotri- 
acetic acid and 0.1% bovine serum albumin. Cofiagenase 
(0.5 mg/ml, Worthington Biochemical Corp., Freehold, 
N.J.; type II, 146 U/rag) was added to the solution and the 
myocardium was perfused for 35 minutes. The tissue was 
then minced into 2 mm sections and added to an oxygen- 
ated solution containing 2% bovine serum albumin, de- 
oxyribonuclease II (DNase, 51 Kunitz units/ml, type IV; 
Sigma Chemical Co., St. Louis, MoO, 300/~mol/L calcium 
chloride, and 0.5 mg/ml collagenase. The supernatant was 
removed and the myocyte pellet was resuspended in 
standard cell culture medium (2 mmol/L Ca 2+, medium 
M199; Life Technologies, Gaithersburg, Md.). A 2 ml 
aliquot of the isolated myocyte suspension was then plated 
onto coverslips coated with a basement membrane sub- 
strate (Matrigel; Collaborative Biomedical Inc., Bedford, 
Mass.), stabilized at 37 ° C in oxygenated medium for 60 
nlinutes, and then randomly assigned to treatment proto- 
cols after measurement of baseline contractile function. 
Viable myocytes included those that retained arod shape, 
were calcium tolerant, and excluded trypan blue dye. The 
percentage of viable myocytes averaged 80% _+ 3%, with 
no significant differences between treatment groups. 
For contractile function measurements, myocytes were 
placed in a thermostatically controlled chamber contain- 
ing standard cell culture medium (37 ° C) for imaging on 
an inverted microscope (Axiovert IM35; Carl Zeiss, 
Oberkochen, Germany). The chamber (2.5 ml) contained 
two stimulating platinum electrodes and a miniature 
thermocouple (CN7100; Omega Engineering, Inc., Stam- 
ford, Conn.). Imaging of myocytes was accomplished with 
a ×20 Hoffman Modulation Contrast Objective (Modula- 
tion Optics, Inc., Greenvale, N.Y.) with a final magnifica- 
tion of × 1100. Myocyte contractions were elicited by field 
stimulating the tissue chamber at 1 Hz (Sll; Grass 
Instrument Co., Quincy, Mass.) with current pulses of 5 
msec duration and voltages 10% above contraction 
threshold. A standard voltage (3 volts) was delivered to 
the medium for all myocytes tudied. Polarity of the 
stimulating electrodes was alternated at every pulse to 
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prevent accumulation of electrochemical byproducts. 
Myocyte contractions were imaged with a charge-coupled 
device with a noninterlaced scan rate of 240 Hz (GPCD 
60; Panasonic Co., Secaucus, N.J.). Myocyte motion sig- 
nals were captured with the cell parallel to the video raster 
lines, and this video signal was input through an edge- 
detector system (Crescent Electronics, Sandy, Utah). 
Changes in light intensity at the myocyte dges were used 
to track myocyte motion. The distance between the left 
and right myocyte edges was converted into a voltage 
signal, digitized, and input to a computer (80286, 
ZBV2526; Zenith Data Systems, St. Joseph, Mich.) for 
subsequent analysis. Stimulated myocytes were allowed a 
5-minute stabilization period after electrical stimulation, 
and contraction data for each myocyte were recorded 
from a minimum of 20 consecutive contractions. Param- 
eters computed from the digitized contraction profiles 
included the following: magnitude of shortening (ex- 
pressed as a percentage), velocity of shortening (in mi- 
crometers per second), velocity of relengthening (in mi- 
crometers per second), time to 50% relaxation (in 
milliseconds), total contraction duration (in milliseconds), 
and time to peak contraction (in milliseconds). Myocyte 
percentage shortening was determined as the percentage 
difference between maximum and minimum cell length for 
each contraction. Myocyte shortening velocity computa- 
tions were obtained by differentiating the digitized con- 
traction profiles. The time to peak contraction was com- 
puted by calculating the time required for the 
differentiated velocity profile to reach zero velocity after 
the start of contraction. All parameters were calculated 
for each contraction and the results were averaged for the 
20 contractions observed. 
Cardioplegia and drug administration. After determi- 
nation of initial myocyte contractile function, myocytes 
were randomly assigned to one of three treatment proto- 
cols. (1) In the normothermic control group, the following 
protocol was performed: Myocytes were incubated at 
37 ° C in Ringer's solution containing 30 mmol/L sodium 
bicarbonate (pH 7.8, 280 mOsm) and then stored for 2 
hours at 37 ° C in a 95% oxygen environment. (2) In the 
cardioplegia group, the following protocol was performed: 
Myocytes were incubated at 4 ° C in Ringer's solution 
containing 24 mEq/L potassium chloride and 30 mEq/L 
sodium bicarbonate (315 mOsm), then stored at 4 ° C for 
2 hours with subsequent rewarming for 10 minutes. (3) In 
the BDM-cardioplegia group, the following protocol was 
performed: Myocytes were incubated at 4 ° C in Ringer's 
solution containing 24 mEq/L potassium chloride, 30 
mEq/L sodium bicarbonate, and 20 mmol/L BDM (453 
mOsm), then stored at 4 ° C for 2 hours with subsequent 
rewarming in standard cell culture medium for 10 min- 
utes. This concentration ofBDM (20 retool/L) was chosen 
because it has been shown to inhibit force development in 
cultured ventricular myocytes and to improve myocardial 
ischemic tolerance without adverse effects on isolated 
myocyte viability. 15, 24 
After the respective treatment protocol and rewarming, 
myocytes were transferred to the stimulation chamber, 
electrical stimulation was initiated, and steady-state 
contractile function measurements were obtained as 
described in the previous ection. Because initial pretreat- 
ment myocyte contractile function did not differ signifi- 
cantly from myocyte contractile function in the normo- 
thermic control group, only values for the normothermic 
control group are reported. After measurement of con- 
tractile function, myocytes were exposed to 25 nmol/L 
isoproterenol and measurements of contractile function 
were repeated. The oxygen tension of the incubation 
medium did not differ significantly between treatment 
groups at the beginning or end of the experimental 
protocol and ranged between 210 and 270 mm Hg. 
Myoeyte dimensions. Resting myocyte length (/xm) was 
measured under normothermic control conditions and 
after hypothermic, hyperkalemic cardioplegic arrest with 
and without BDM supplementation f the cardioplegia 
solution. To examine more carefully the issue of myocyte 
swelling after cardioplegic arrest, myocytes from the nor- 
mothermic ontrol group, cardioplegia group, and BDM- 
cardioplegia group were immediately placed in a buffered 
sodium cacodylate solution containing 2% paraformalde- 
hyde and 2% glutaraldehyde (pH 7.4, 325 mOsm). The 
isolated myocytes were then imaged with a ×10 phase- 
contrast objective. The image was input into an image- 
analysis ystem (IBAS 2000 Image Analysis System; Carl 
Zeiss) and the images were digitized at 512 × 512 line 
resolution and 256 gray levels. Individual cell profiles were 
automatically discriminated by gray level to determine 
myocyte profile surface areaY 
Data analysis. Changes in indexes of myocyte function 
between the control and cardioplegia groups were exam- 
ined with multiway analysis of variance. If analysis of 
variance revealed significant differences, pairwise tests of 
individual group means were compared with Bonferroni's 
probabilities. All statistical analyses were performed with 
standard statistical software programs (BMDP Statistical 
Software Inc., University of California Press, Los Angeles, 
Calif.). Results are presented as mean 2 standard error of 
the mean. Values of p < 0.05 were considered to be 
statistically significant. 
Results 
Representative contraction profiles at baseline for 
normothermic ontrol and cardioplegia myocytes 
are illustrated in Fig. 1, and steady-state myocyte 
contractile function for these two treatment groups 
is summarized in Table I. A significant reduction in 
contractile function was observed for myocytes ex- 
posed to hypothermic, hyperkalemic ardioplegic 
arrest and rewarming. Specifically, isolated myocyte 
velocity of shortening was reduced by 32% and 
myocyte percentage shortening was reduced by 27% 
in the cardioplegia group relative to the normother-  
mic control group. The velocity of relengthening, 
which is an index of active relaxation, was signifi- 
cantly decreased by 33% in myocytes after hy- 
perkalemic ardioplegic arrest. 
To determine the effect of BDM supplementation 
on myocyte contractile function after hypothermic, 
hyperkalemic ardioplegic arrest, 20 mmol/L BDM 
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Fig. 1. Representative contraction profiles for myocytes from the normothermic control, cardioplegia, nd 
BDM-cardioplegia treatment groups. The extent of myocyte shortening with each contraction was 
significantly reduced for myocytes after hyperkalemic cardioplegic arrest. The addition of BDM to the 
cardioplegia solution restored myocyte shortening after hyperkalemic cardioplegic arrest o normothermic 
control values. 
was included in the standard cardioplegic solution 
for the 2-hour incubation period. Steady-state myo- 
cyte contractile function from this portion of the 
study is illustrated in Table I. BDM supplementa- 
tion preserved myocyte contractile function after 
hypothermic, hyperkalemic cardioplegic arrest. 
There were no differences in velocity of shortening, 
percentage shortening, or velocity of relengthening 
between myocytes in the BDM-cardioplegia nd 
normothermic control groups. A significant increase 
in velocity of shortening (21%) and percentage 
shortening (23%) was observed in myocytes with 
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BDM supplementation (BDM-cardioplegia group) 
relative to myocytes that underwent cardioplegic 
arrest without BDM supplementation (cardioplegia 
group). Moreover, a significant increase (62%) in 
velocity of relengthening was measured in myocytes 
in the BDM-cardioplegia group relative to myocytes 
in the cardioplegia group. The time to 50% relax- 
ation was significantly reduced in myocytes in the 
BDM-cardioplegia group relative to both normo- 
thermic control and cardioplegia groups. 
To determine the effects of BDM supplementa- 
tion on/3-adrenergic responsiveness after hypother- 
mic, hyperkalemic ardioplegic arrest, 25 nmol/L 
isoproterenol was added to the medium of myocytes 
in the normothermic ontrol, cardioplegia, and 
BDM-cardioplegia groups. The concentration of 25 
nmol/L isoproterenol used in this study has been 
shown to produce a maximal contractile response in 
normothermic ontrol myocytes. 8' 9,23 The results 
for /3-adrenergic stimulation are summarized in 
Table I. Isoproterenol resulted in a significant in- 
crease in myocyte contractile function in normother- 
mic control, cardioplegia, and BDM-cardioplegia 
groups. The velocity of shortening and percentage 
shortening increased by more than 150% in all 
myocyte treatment groups. Contractile function, 
however, of cardioplegia myocytes after isoprotere- 
nol administration remained significantly decreased 
compared with normothermic ontrol myocytes. 
Cardioplegia supplementation with BDM signifi- 
cantly improved 13-adrenergic responsiveness after 
cardioplegic arrest to values observed with normo- 
thermic ontrol myocytes. Myocytes exposed to car- 
dioplegic arrest with BDM supplementation dis- 
played significantly increased percentage and 
velocity of shortening relative to myocytes exposed 
to cardioplegic arrest without BDM supplementa- 
tion after isoproterenol administration. Moreover, 
velocity of relengthening for myocytes after car- 
dioplegic arrest and isoproterenol administration 
was significantly higher (33%) when BDM Supple- 
mentation was used. There were no differences in 
myocyte contractile indexes between ormothermic 
control and BDM-cardioplegia myocytes after iso- 
proterenol administration, with the exception of a 
reduced time to peak contraction and decreased 
total contraction duration observed in myocytes in 
the BDM-cardioplegia group. 
To determine the effect of BDM on myocyte 
dimensions after hypothermic, hyperkalemic ar- 
dioplegic arrest, isolated myocyte profile surface 
area was measured by means of computer digitiza- 
Table I. Effects of BDM supplementation 
myocyte contractile function after hypotherrnic 
hypervolemic cardiopIegic arrest 
Isoproterenol 
Baseline (25 nmol/L) 
Resting length (/xm) 
Normothermic control 139 +_ 3 134 _+ 3 
Cardioplegia 132 _+ 3 128 -+ 3 
BDM-cardioplegia 134 +_ 3 130 + 3 
Velocity of shortening 0,m/sec) 
Normothermic control 50 _+ 3 154 + 9* 
Cardioplegia 34 _+ i t  130 + 5"? 
BDM-cardioplegia 43 ± 2~- 166 -+ 8*$ 
Shortening (%) 
Normothermic control 4.5 ± 0.1 9.5 -+ 0.3* 
Cardioplegia 3.3 _+ OAt 8.6 + 0.3*? 
BDM-cardioplegia 4.3 _+ 0.2:) 10.1 + 0.4*$ 
Velocity of relengthening 
(/,m/sec) 
Normothermic control 55 ± 3 139 -+ 9* 
Cardioplegia 37 _+ 2? 115 _+ 6*t 
BDM-cardioplegia 60 ± 4~ 153 ± 9*+.- 
Time to 50% relaxation (msec) 
Normothermic control 95 ± 3 77 + 2* 
Cardioplegia 100 ± 4 81 + 4* 
BDM-cardioplegia 84 ± 27:~ 76 ± 3* 
Time to peak contraction 
(msec) 
Normothermic control 266 ± 7 220 _+ 6* 
Cardioplegia 255 +_ 5 190 ± 4*t 
BDM-cardioplegia 259 _+ 5 188 ± 4*t 
Total contraction duration 
(msec) 
Normothermic control 474 _+ 12 402 -- 8* 
Cardioplegia 464 +_ 9 388 ± 11" 
BDM-cardioplegia 448 _+ 7 371 +_ 9"1 
Number of myocytes 
Normethermic control 67 64 
Cardioplegia 70 68 
BDM-cardioplegia 82 78 
*p < 0.05 vs baseline. 
tp < 0.05 vs normothermic control. 
Sp < 0.05 vs cardioplegia. 
tion methods for normothermic ontrol myocytes 
and myocytes after cardioplegic arrest, with and 
without BDM supplementation. As illustrated in 
Fig. 2, myocyte profile surface area formed a Gaus- 
sian distribution in the normothermic control group, 
with a mean value of 3445 +- 47/xm 2. Hypothermic, 
hyperkalemic cardioplegic arrest resulted in a signif- 
icant increase in myocyt e profile surface area to 
4024 _+ 56/xm 2 (p < 0.05). BDM supplementation 
resulted in a significant reduction in myocyte surface 
area after cardioplegic arrest to 3312 + 42 /xm 2 
(p < 0.05), a value comparable with normothermic 
control myocytes. 
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Fig. 2. Profile surface area for myocytes from the normothermic control, cardioplegia, and BDM- 
cardioplegia treatment groups. Profile surface area formed a Gaussian distribution. A significant increase 
in myocyte profile surface area occurred after hyperkalemic cardioplegic arrest. BDM supplementation of 
the cardioplegia solution prevented the increase in myocyte profile surface area associated with 
hyperkalemic cardioplegic arrest. 
Discussion 
Despite significant advances in myocardial pres- 
ervation techniques, a reduction in left ventricular 
function still occurs after hypothermic, hyperkale- 
mic cardioplegic arrest, and plays a major role in 
patient morbidity) The cellular basis and contribu- 
tory mechanisms involved in such ventricular dys- 
function after hypothermic, hyperkalemic cardiople- 
gic arrest remain unclear but may involve an excess 
of intracellular calcium associated with a hyperkale- 
mic extracellular milieu. 6' 7 This study demonstrates 
for the first time that the deleterious effects of 
hypothermic, hyperkalemic ardioplegic arrest on 
contractile function, /3-receptor stimulation, and 
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volume regulatory processes within the myocyte can 
be prevented by the addition of BDM to the hy- 
perkalemic ardioplegia solution. 
The mechanism through which BDM preserved 
isolated myocyte contractile function in this study 
after hyperkalemic cardioplegic arrest is speculative, 
but is probably related to prevention of widespread 
cellular damage of myocytes caused by an overload 
of intracellular calcium. 11'26' 27 The hyperkalemic 
environment associated with cardioplegia has been 
shown to induce an increase in intracellular calcium 
by several mechanisms, including increased trans- 
sarcolemmal calcium flux through slow calcium 
channels, potentiation of calcium release from the 
sarcoplasmic reticulum, and increase in calcium 
influx through sodium-calcium exchange activi- 
ty.6, 7, 2s-30 This calcium overload state during car- 
dioplegic arrest is further enhanced by an increase 
in cytosolic levels of free calcium that occurs with 
either ischemia or prolonged metabolic inhibition 
and contributes to calcium-induced myocyte dam- 
age. 1214 BDM has been shown to decrease intracel- 
lular calcium transients by reducing the transsar- 
colemmal calcium flux and decreasing the release of 
calcium from the sarcoplasmic reticulum. 18'2°-22 
Moreover, BDM can result in a reduction in myofi- 
brillar sensitivity to calcium. 17-~9 BDM has also been 
shown to uncouple myocardial excitation from con- 
traction, presumably by a direct action on myosin 
molecules, and to protect ischemic myocardium 
from calcium-stimulated ATP loss and the damag- 
ing effects of ischemic ontracture. 15' 16, 31 There is 
also evidence that the inhibition of calcium-depen- 
dent force development by BDM can protect against 
reoxygenation hypercontracture in ventricular myo- 
cytes. 26 Such reductions in intracellular f ee calcium 
and attenuation of calcium effects may therefore be 
responsible for the protective ffect of BDM on 
myocyte contractile function after hyperkalemic car- 
dioplegic arrest observed in this study. Direct mea- 
surements of intracellular calcium during hyperkale- 
mic cardioplegic arrest and reperfusion with and 
without BDM supplementation would be useful to 
determine the contribution of alterations in cyto- 
solic calcium transients to the protective ffect ob- 
served. 
One frequent consequence of hypothermic hy- 
perkalemic ardioplegic arrest is myocardial ede- 
ma. 32 With reperfusion after cardioplegic arrest, 
myocardial water content can increase, resulting in a 
reduction in left ventricular compliance, which in 
turn contributes to a deterioration i left ventricular 
performance.32, 3 In a previous tudy by this labo- 
ratory, we determined that a significant increase in 
isolated myocyte profile surface area occurred after 
hypothermic, hyperkalemic cardioplegic arrest, 
showing that the intracellular compartment partici- 
pates in the myocardial edema observed in vivo. s' 32 
The increase in myocyte profile surface area after 
hyperkalemic ardioplegic arrest is indicative of 
marked cellular swelling, since surface area is di- 
rectly proportional to myocyte volume. 34 In the 
present study, BDM supplementation f the cardio- 
plegia solution prevented the cellular swelling ob- 
served after hyperkalemic cardioplegic arrest. These 
results indicate that the disruption of cell volume 
regulatory processes associated with hyperkalemic 
cardioplegic arrest were prevented by the presence 
of BDM, which may reflect improvement of ionic 
homeostasis by BDM supplementation during hy- 
perkalemic ardioplegic arrest. 
In this study, the velocity of myocyte relengthen- 
ing, which is an index of active relaxation processes 
and diastolic function, was significantly reduced 
after hypothermic hyperkalemic cardioplegic arrest. 
Increased intracellular calcium concentrations in 
diastole after reperfusion have been shown to be 
associated with a significant reduction of ventricular 
compliance and impaired relaxation, with actin- 
myosin cross-bridge formation and depletion of 
ATP levels. 35 The capacity for the sarcoplasmic 
reticulum of a postischemic myocyte to participate 
in the uptake of calcium may be impaired, which 
would result in increased iastolic intracellular cal- 
cium concentrations. 36' 37 The impairment of dia- 
stolic myocyte contractile function after hypother- 
mic, hyperkalemic ardioplegic arrest has been 
shown to be especially pronounced in the presence 
of elevated extracellular calcium concentration, sug- 
gesting a potentiation of intracellular calcium over- 
load in diastole through passive diffusion. 8 In this 
study, BDM supplementation restored active relax- 
ation of myocytes after cardioplegic arrest to nor- 
mothermic ontrol values, which may in part reflect 
BDM-induced alterations in calcium transients. In 
fact, the time to 50% relaxation was reduced in 
myocytes after cardioplegic arrest with BDM sup- 
plementation compared with normothermic control 
myocytes, which again confirms improved diastolic 
function. This finding agrees with studies of whole- 
heart preparations undergoing prolonged hypother- 
mic preservation i  which BDM supplementation 
was shown to improve diastolic relaxation. 15'16 
BDM inhibits actin-myosin cross-bridge formation 
6 2 8 Dorman et al. 
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and causes a decrease in myosin ATPase activity, 
which helps preserve ATP levels during arrest. 15' 38 
Because active relaxation is an energy-dependent 
process, the preservation of ATP levels by BDM 
may contribute to the improved diastolic function. 
An increase in myocyte contractile function was 
caused by /3-adrenergic stimulation both in the 
normothermic control group and after hyperkalemic 
cardioplegic arrest. In agreement with previous 
studies, however, /3-adrenergic responsiveness was 
reduced after hyperkalemic ardioplegic arrest, s'9 
The decrease in/3-receptor density, concurrent with 
desensitization a d down regulation of the/3-recep- 
tor system that has been shown to occur after 
hyperkalemic cardioplegic arrest, probably plays a 
major role in the reduced/3-adrenergic responsive- 
ness observed. 39 It is also possible that elevated 
levels of cytosolic alcium during hyperkalemic car- 
dioplegic arrest may have caused intracellular dam- 
age and thereby reduced activity downstream from 
the /3-adrenergic receptor system, affecting phos- 
phorylation and integrity of calcium channels, or 
affecting actin-myosin complex cross-bridge cy- 
cling.40, 41 BDM supplementation of cardioplegia 
restored /3-adrenergic responsiveness of myocytes 
after hyperkalemic cardioplegic arrest, which may in 
part reflect prevention of calcium-induced cellular 
damage.11, i5, 26, 42 There is also evidence that syn- 
ergy exists between cyclic adenosine monophos- 
phate and ATP in signal transduction in cardiac 
myocytes, potentiating an inward calcium current 
during the action potential. 43 Preservation of ATP 
during hyperkalemic ardioplegic arrest by BDM 
may result in a potentiation of the /3-adrenergic 
response due to this synergism between ATP and 
cyclic adenosine monophosphate. 
The isolated myocyte model used in this study 
allows measurement of contractile function in a 
precisely controlled extracellular milieu so that di- 
rect influences of agents such as BDM can be 
determined. Examination of contractile properties 
of isolated myocytes has other distinct advantages, 
including the removal of both loading conditions 
and neurohormonal ctivity, which could potentially 
influence ventricular performance in vivo, and the 
ability to directly measure contractile function inde- 
pendent of the effects of alterations in coronary 
perfusion. Although the isolated myocyte model has 
the advantage of direct measurements of myocyte 
contractile function, it also has several imitations. 
The buffering influence of extracellular proteins, 
which may play an important role in vivo, is not 
present. Moreover, myocytes in the cardioplegic 
arrest groups were continuously exposed to an ele- 
vated potassium concentration without magnesium 
for the entire 2-hour incubation period, which dif- 
fers from many intermittent multidose cardioplegia 
techniques used clinically. These limitations, how- 
ever, also reveal the strength of the isolated myocyte 
model, because an examination can be made of the 
direct effects of cardioplegic arrest on the myocyte, 
the basic functional unit of the heart. 
In summary, BDM prevented reductions in myo- 
cyte contractile function, /3-adrenergic responsive- 
ness, and cellular swelling after hypothermic, hy- 
perkalemic ardioplegic arrest. This study provides 
for the first time direct evidence that the deleterious 
effects of cardioplegic arrest on myocyte contractile 
function, volume regulation, and active relaxation 
can be prevented with BDM supplementation f the 
cardioplegia solution. In light of the fact that BDM 
decreases intracellular calcium transients, these 
findings suggest hat the mechanism of action of 
BDM supplementation during hyperkalemic ar- 
dioplegic arrest is improved calcium homeostasis. 
Although additional research is required, BDM 
supplementation holds clinical promise as an ad- 
junct for myocardial protection with cardioplegic 
arrest. 
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